Search

Your search keyword '"Lopez Longo, Francisco Javier"' showing total 3 results
Start Over Author "Lopez Longo, Francisco Javier" Publication Type Magazines
3 results on '"Lopez Longo, Francisco Javier"'

1. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Khanna, Dinesh, Lin, Celia J F, Furst, Daniel E, Goldin, Jonathan, Kim, Grace, Kuwana, Masataka, Allanore, Yannick, Matucci-Cerinic, Marco, Distler, Oliver, Shima, Yoshihito, van Laar, Jacob M, Spotswood, Helen, Wagner, Bridget, Siegel, Jeffrey, Jahreis, Angelika, Denton, Christopher P, Lucero, Eleonora, Pons-Estel, Bernardo, Rivero, Mariano, Tate, Guillermo, Smith, Vanessa, De Langhe, Ellen, Rashkov, Rasho, Batalov, Anastas, Goranov, Ivan, Stoilov, Rumen, Dunne, James, Johnson, Sindhu R., Pope, Janet E., Martinović Kaliterna, Dušanka, Mogensen, Mette, Olesen, Anne Braae, Allanore, Yannick, Henes, Joerg Christoph, Müller-Ladner, Ulf, Riemekasten, Gabriela, Skapenko, Alla, Vlachoyiannopoulos, Panayiotis, Kiss, Emese, Minier, Tünde, Beretta, Lorenzo, Gremese, Elisa, Matucci-Cerinic, Marco, Valentini, Gabriele, Asano, Yoshihide, Atsumi, Tatsuya, Ihn, Hironobu, Ishii, Tomonori, Ishikawa, Osamu, Kuwana, Masataka, Shima, Yoshihito, Takahashi, Hiroki, Takehara, Kazuhiko, Tanaka, Yoshiya, Yamasaki, Yoshioki, Bukauskiene, Loreta, Butrimiene, Irena, Medrano Ramirez, Gabriel, Ramos-Remus, Cesar, Sofia Rodriguez Reyna, Tatiana, de Vries-Bouwstra, Jeska, van Laar, Jacob M., Batko, Bogdan, Jeka, Slawomir, Kucharz, Eugeniusz, Majdan, Maria, Olesinska, Marzena, Smolenska, Zaneta, Alves, Jose, Santos, Maria, Mihai, Carmen Marina, Rednic, Simona, Castellvi Barranco, Ivan, Lopez Longo, Francisco Javier, Simeon Aznar, Carmen, Carreira, Patricia, Distler, Oliver, Walker, Ulrich A., Derrett-Smith, Emma, Griffiths, Bridget, McKay, Neil, Denton, Christopher P., Aelion, Jacob, Borofsky, Michael, Fleischmann, Roy, Forstot, Joseph Z., Furst, Daniel E., Kafaja, Suzanne, Khan, M. Faisal, Khanna, Dinesh, Kohen, Michael D., Martin, Richard W., Mendoza-Ballesteros, Fabian, Nami, Alireza, Pang, Shirley, Rios, Grissel, Simms, Robert, Sullivan, Keith Michael, and Steen, Virginia D.

Abstract

A phase 2 trial of tocilizumab showed preliminary evidence of efficacy in systemic sclerosis. We assessed skin fibrosis and systemic sclerosis-associated interstitial lung disease (SSc-ILD) in a phase 3 trial to investigate the safety and efficacy of tocilizumab, an anti-interleukin-6 receptor antibody, in the treatment of systemic sclerosis.

Published
2020
Full Text
View/download PDF

2. Nailfold Capillaroscopy Characteristics of Antisynthetase Syndrome and Possible Clinical Associations: Results of a Multicenter International Study

Author

Sebastiani, Marco, Triantafyllias, Konstantinos, Manfredi, Andreina, González-Gay, Miguel Angel, Palmou-Fontana, Natalia, Cassone, Giulia, Drott, Ulrich, Delbrück, Christiane, Rojas-Serrano, Jorge, Bertolazzi, Chiara, Nuño, Laura, Giannini, Margherita, Iannone, Florenzo, Vicente, Esther F., Castañeda, Santos, Selva-O’Callaghan, Albert, Trallero Araguas, Ernesto, Emmi, Giacomo, Iuliano, Annamaria, Bauhammer, Jutta, Miehle, Nikolaus, Parisi, Simone, Cavagna, Lorenzo, Codullo, Veronica, Montecucco, Carlomaurizio, Lopez-Longo, Francisco Javier, Martínez-Barrio, Julia, Nieto-González, Juan Carlos, Vichi, Silvia, Confalonieri, Marco, Tomietto, Paola, Bergner, Raoul, Sulli, Alberto, Bonella, Francesco, Furini, Federica, Scirè, Carlo Alberto, Bortoluzzi, Alessandra, Specker, Christof, Barsotti, Simone, Neri, Rossella, Mosca, Marta, Caproni, Marzia, Weinmann-Menke, Julia, Schwarting, Andreas, Smith, Vanessa, and Cutolo, Maurizio

Abstract

Objective.To describe nailfold videocapillaroscopy (NVC) features of patients with antisynthetase syndrome (AS) and to investigate possible correlations with clinical and serological features of the disease.Methods.We retrospectively analyzed NVC images of 190 patients with AS [females/males 3.63, mean age 49.7 ± 12.8 yrs, median disease duration 53.7 mos (interquartile range 82), 133 anti-Jo1 and 57 non–anti-Jo1-positive patients]. For each patient, we examined number of capillaries, giant capillaries, microhemorrhages, avascular areas, ramified capillaries, and the presence of systemic sclerosis (SSc)-like pattern. Finally, we correlated NVC features with clinical and serological findings of patients with AS. Concomitantly, a historical cohort of 75 patients with antinuclear antibody–negative primary Raynaud phenomenon (RP) and longterm followup was used as a control group (female/male ratio 4.13/1, mean age 53.9 ± 17.6 yrs) for NVC measures.Results.NVC abnormalities were observed in 62.1% of AS patients compared with 29.3% of primary RP group (p < 0.001). An SSc-like pattern was detected in 67 patients (35.3%) and it was associated with anti-Jo1 antibodies (p = 0.002) and also with a longer disease duration (p = 0.004). Interestingly, there was no significant correlation between the presence of SSc-like pattern and RP, and only 47% of patients with SSc-like pattern had RP.Conclusion.NVC abnormalities are commonly observed in AS, independently from the occurrence of RP. The presence of an SSc-like pattern could allow identification of a more defined AS subtype, and prospective studies could confirm the association with clinical and serological features of AS.

Published
2019
Full Text
View/download PDF

3. Lack of Association with Rheumatoid Arthritis of Selected Polymorphisms in 4 Candidate Genes: CFH, CD209, Eotaxin-3, and MHC2TA

Author

DIEGUEZ-GONZALEZ, REBECA, AKAR, SERVET, CALAZA, MANUEL, GONZALEZ-ALVARO, ISIDORO, FERNANDEZ-GUTIERREZ, BENJAMIN, LAMAS, JOSE RAMON, de la SERNA, ARTURO R., CALIZ, RAFAEL, BLANCO, FRANCISCO J., PASCUAL-SALCEDO, DORA, VELLOSO, MARIA LUISA, PEREZ-PAMPIN, EVA, PABLOS, JOSE LUIS, NAVARRO, FEDERICO, NARVAEZ, JAVIER, LOPEZ-LONGO, FRANCISCO JAVIER, HERRERO-BEAUMONT, GABRIEL, GOMEZ-REINO, JUAN J., and GONZALEZ, ANTONIO

Abstract

OBJECTIVE: To investigate associations with rheumatoid arthritis (RA) of single-nucleotide polymorphisms (SNP) in 4 candidate genes, complement factor H (CFH), CD209 or DC-SIGN, eotaxin-3, and the MHC class II Transactivator (MHC2TA) genes. These SNP have been reported as important for RA (eotaxin-3 and MHC2TA) or for other immune-mediated diseases (CFH and CD209). METHODS: Genotypes for the 7 selected SNP were obtained from 1587 patients with RA and 1570 controls of Spanish ancestry. Analyses were carried out after stratification for sex, erosions, rheumatoid factor, shared epitope, anti-cyclic citrullinated peptide antibodies, and the R620W PTPN22 SNP. RESULTS: None of the comparisons between patients with RA and controls or between the different strata of patients according to disease features was significant. CONCLUSION: None of the SNP in CFH and CD209 showed evidence of association with RA. We did not replicate the association of eotaxin-3 with RA described in Koreans, or that of the MHC2T SNP.

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results